SynthesisClinical cardiology2023
Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: A systematic review.
Synthesis in Clinical cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Cardiology Consult for the General Pediatrician after Cardiac Manifestations from a SARS-CoV-2 Infection.Current pediatric reviews · 2026Pooled it
- Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: A systematic review.Clinical cardiology · 2023Pooled it
- Myocarditis after COVID-19 mRNA vaccination in Norway: a nationwide validation study.Open heart · 2026Observational
- Critical Evaluation of the Impact of COVID-19 Pandemic on Child Health and Wellbeing and Suggested Preparedness for Future Pandemics-A Narrative Review.Health science reports · 2026Article
- C-reactive protein in cardiovascular disease: clinical associations, conformation-dependent biology, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Trends of Cardiac Complaints in Pediatric and Young Adult Populations During the COVID-19 Pandemic.Journal of cardiovascular development and disease · 2025Article
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- Immune and hematologicak responses to the third dose of an mRNA COVID-19 vaccine: a six-month longitudinal study.Frontiers in cellular and infection microbiology · 2025Article
- An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.Immunity, inflammation and disease · 2024Review
- Emergency department presentations for chest complaints after mRNA COVID-19 vaccinations in children and adolescents.Emergency medicine Australasia : EMA · 2024Article
- Article
- The ethicality of the COVID-19 response in children and adolescents.Irish journal of medical science · 2024Article
- Postvaccine myocarditis and the use of antipyretics: Is there any relation?Clinical cardiology · 2023Article
- Antipyretics and vaccine-induced myocarditis.Clinical cardiology · 2023Article
- Development of myocarditis and pericarditis after COVID-19 vaccination: A deeper insight.Clinical cardiology · 2023Article
- Development of myocarditis and pericarditis after COVID-19 vaccination: Comment.Clinical cardiology · 2023Article
- Cardiac Arrhythmias in Post-COVID Syndrome: Prevalence, Pathology, Diagnosis, and Treatment.Viruses · 2023Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis and pericarditis have been reported after COVID-19 vaccine administration in children and adolescents, raising the concern about their possible association with these vaccines. The objective was to explore the incidence, clinical presentation, and association of myocarditis and pericarditis with COVID-19 vaccines in children and adolescents. We conducted a systematic literature search on three databases, that is, Cochrane, MEDLINE/PubMed, and EMBASE from inception till March 2022. A total of three case reports, four case series, and six observational studies were included in the review. For case reports and case series, the mean age of the patients was 17.4 years, with 96.9% being male. Chest pain (n = 31, 93.9%), fever (n = 18, 54.5%), myalgias (n = 15, 45.4%) and headache (n = 9, 27.2%) were the most common presentations. Out of 33 patients, 32 (96.9%) of patients received Pfizer-BioNTech whereas only one (3.03%) received Moderna (mRNA 1273). Clinical investigations revealed ST elevation (n = 32, 97%), and elevated CRP (n = 9, 27.2%) and cardiac troponin (n = 29, 87.8%). The pooled incidence of myocarditis and pericarditis from observational studies was (0.00063%) and (0.000074%) %, respectively. Myocarditis and pericarditis in children and adolescents after the COVID-19 vaccines were more prevalent among males and more commonly observed after the second dose of Pfizer. Though the overall incidence was low, however, the clinicians should consider myocarditis and pericarditis as probable diagnosis when encountering young patients, with a history of vaccine administration, presenting with suggestive findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.